XML 53 R36.htm IDEA: XBRL DOCUMENT v3.24.1
Organization and Nature of the Business - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Aug. 31, 2022
Mar. 12, 2021
Jan. 31, 2024
Nov. 30, 2022
Dec. 31, 2023
Dec. 31, 2022
Schedule Of Equity Method Investments [Line Items]            
Accumulated deficit         $ 380,772 $ 238,114
Proceeds from issuance of common stock pursuant to at-the-market offering, net of issuance costs         0 $ 43,360
aggregate net proceed         19,300  
Public Offering Underwritten         $ 91,800  
Common stock, shares outstanding         43,270,386 42,954,820
Sales Agreement [Member]            
Schedule Of Equity Method Investments [Line Items]            
Proceeds from issuance of common stock pursuant to at-the-market offering, net of issuance costs       $ 100,000    
Aggregate number of shares sold 2,611,723          
Sale of Stock, Price Per Share $ 17.23          
Sales agent commissions and expenses $ 43,400          
Common Stock not sold       30,000    
Additional Common Stock not sold       $ 70,000    
ATM Program [Member]            
Schedule Of Equity Method Investments [Line Items]            
Number of common stock shares sold         0  
Subsequent Event | ATM Program [Member]            
Schedule Of Equity Method Investments [Line Items]            
Proceeds from issuance of common stock pursuant to at-the-market offering, net of issuance costs     $ 19,300      
Maximum [Member] | Sales Agreement [Member]            
Schedule Of Equity Method Investments [Line Items]            
Proceeds from issuance of common stock pursuant to at-the-market offering, net of issuance costs   $ 75,000        
Adicet Therapeutics [Member]            
Schedule Of Equity Method Investments [Line Items]            
Accumulated deficit         $ (380,800)